← Patent-cliff monitor small molecule ROZLYTREK ENTRECTINIB
Loss of exclusivity July 2038 latest FDA-listed patent expiry
Company Genentech → View the full company profile on CliffBio Drug detail Brand name ROZLYTREK Active ingredient ENTRECTINIB Strength 100MG Dosage form CAPSULE Route ORAL Modality Small molecule FDA approval August 2019 Marketing status RX
Listed patents Patent Expires Type 10398693 July 2038 product 11253515 July 2038 product 11091469 May 2037 use U-2618 10738037 May 2037 substance, product 10561651 February 2035 use U-2745 10231965 February 2035 use U-2617 9085565 May 2033 substance, product 9649306 May 2033 use U-2617 8299057 March 2032 substance, product 9085558 July 2028 product 9029356 July 2028 substance, product 9255087 July 2028 use U-2617 8673893 July 2028 use U-2617 9616059 July 2028 use U-2618
Regulatory exclusivity Code Expires ODE-448 October 2030 NPP October 2026 ODE-265 August 2026 ODE-313 August 2026
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.